On October 20, 2023 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that it will host a virtual key opinion leader (KOL) event highlighting the current state of lung cancer treatments and the challenges facing patients (Press release, Genprex, OCT 20, 2023, View Source [SID1234636176]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event details are as follows:
Bringing Gene Therapy to the Fight Against Lung Cancers
Date and Time: October 27, 2023 at 12:30 pm – 1:45 pm ET
Webinar Registration Link: Click Here
The event will feature discussion with:
Alexander I. Spira, MD, PhD, FACP, Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program at Johns Hopkins Hospital; a medical oncologist who specializes in the treatment of lung cancers.
Daniel Morgensztern, MD, Professor of Medicine, and Director of Thoracic Oncology at Washington University School of Medicine; a medical oncologist who specializes in the treatment of lung and esophageal cancers.
The event will be moderated by Mark S. Berger, MD, Chief Medical Officer at Genprex, and will highlight REQORSA (quaratusugene ozeplasmid) as a potential treatment for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The webinar will conclude with a question and answer session with the audience.
A webcast of the event will be available on the investor relations page of the Genprex website at Videos Archive – Genprex. A replay of the webcast will be archived on Genprex’s website for a period of time.
About REQORSA Immunogene Therapy
REQORSA (quaratusugene ozeplasmid) for NSCLC and SCLC consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (Genprex’s ONCOPREX Nanoparticle Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing its uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells.